Endonovo Therapeutics, Inc. – OTC:ENDV
Endonovo Therapeutics stock price today
Endonovo Therapeutics stock price monthly change
Endonovo Therapeutics stock price quarterly change
Endonovo Therapeutics stock price yearly change
Endonovo Therapeutics key metrics
Market Cap | 2.91M |
Enterprise value | 10.01M |
P/E | -0.88 |
EV/Sales | 704.70 |
EV/EBITDA | -7.94 |
Price/Sales | 196.75 |
Price/Book | -0.14 |
PEG ratio | 0.01 |
EPS | N/A |
Revenue | 61.08K |
EBITDA | -2.16M |
Income | -1.01M |
Revenue Q/Q | -90.42% |
Revenue Y/Y | -72.31% |
Profit margin | -22145.06% |
Oper. margin | -22206.38% |
Gross margin | 1.57% |
EBIT margin | -22206.38% |
EBITDA margin | -3546.08% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEndonovo Therapeutics stock price history
Endonovo Therapeutics stock forecast
Endonovo Therapeutics financial statements
| Jun 2023 | 45.2K | 2.06M | 4565.62% |
|---|---|---|---|
| Sep 2023 | 1.52K | -766.17K | -50405.92% |
| Dec 2023 | 5.98K | -1.60M | -26803.71% |
| Mar 2024 | 8.38K | -709.37K | -8463.09% |
| Jun 2023 | 1014821 | 23.21M | 2287.75% |
|---|---|---|---|
| Sep 2023 | 815764 | 23.77M | 2914.56% |
| Dec 2023 | 639656 | 24.74M | 3868.65% |
| Mar 2024 | 476296 | 25.27M | 5307% |
| Jun 2023 | -165.84K | 0 | 187.5K |
|---|---|---|---|
| Sep 2023 | -65.36K | 0 | 32.76K |
| Dec 2023 | 526.23K | 0 | -524.39K |
| Mar 2024 | -2.20K | 0 | 573 |
Endonovo Therapeutics alternative data
| Aug 2023 | 1 |
|---|---|
| Sep 2023 | 1 |
| Oct 2023 | 1 |
| Nov 2023 | 1 |
| Dec 2023 | 1 |
| Jan 2024 | 1 |
| Feb 2024 | 1 |
| Mar 2024 | 1 |
| Apr 2024 | 1 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Endonovo Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2019 | 295500 | 0 |
| Sep 2019 | 138300 | 0 |
| Oct 2019 | 46600 | 0 |
| Nov 2019 | 27000 | 0 |
| Dec 2019 | 14000 | 0 |
| Jan 2020 | 200 | 0 |
| Feb 2020 | 100 | 0 |
| Jun 2020 | 200 | 0 |
| Jul 2020 | 200 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $0.1 | $10 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $0.1 | $10 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 200 | $0.1 | $21 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $0.97 | $97 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $1.75 | $175 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $1.75 | $175 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $1.75 | $175 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $1.75 | $175 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $1.5 | $150 | ||
Purchase | COLLIER ALAN BRIAN officer: CEO | Common Stock | 100 | $0 | $0 |
-
What's the price of Endonovo Therapeutics stock today?
One share of Endonovo Therapeutics stock can currently be purchased for approximately $0.
-
When is Endonovo Therapeutics's next earnings date?
Unfortunately, Endonovo Therapeutics's (ENDV) next earnings date is currently unknown.
-
Does Endonovo Therapeutics pay dividends?
No, Endonovo Therapeutics does not pay dividends.
-
How much money does Endonovo Therapeutics make?
Endonovo Therapeutics has a market capitalization of 2.91M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.61% to 140.24K US dollars.
-
What is Endonovo Therapeutics's stock symbol?
Endonovo Therapeutics, Inc. is traded on the OTC under the ticker symbol "ENDV".
-
What is Endonovo Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Endonovo Therapeutics?
Shares of Endonovo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Endonovo Therapeutics's key executives?
Endonovo Therapeutics's management team includes the following people:
- Mr. Alan Brian Collier Chairman, Chief Executive Officer, Interim Chief Financial Officer & Sec.(age: 59, pay: $300,000)
-
How many employees does Endonovo Therapeutics have?
As Jul 2024, Endonovo Therapeutics employs 1 workers.
-
When Endonovo Therapeutics went public?
Endonovo Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 3 Jan 2013.
-
What is Endonovo Therapeutics's official website?
The official website for Endonovo Therapeutics is endonovo.com.
-
Where are Endonovo Therapeutics's headquarters?
Endonovo Therapeutics is headquartered at 6320 Canoga Avenue, Woodland Hills, CA.
-
How can i contact Endonovo Therapeutics?
Endonovo Therapeutics's mailing address is 6320 Canoga Avenue, Woodland Hills, CA and company can be reached via phone at +800 4894774.
Endonovo Therapeutics company profile:
Endonovo Therapeutics, Inc.
endonovo.comOTC
1
Biotechnology
Healthcare
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Woodland Hills, CA 91367
CIK: 0001528172
ISIN: US29272H3003
CUSIP: 29272H300
